Wockhardt LimitedNSE: WOCKPHARMA

Press Release Jan 13 2025

· Issued by Wockhardt Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Wockhardt Limited submitted a press release regarding the clinical efficacy of Zaynich in treating serious infections caused by resistant pathogens. The study showed that Zaynich achieved high efficacy rates in various severe infections, including bloodstream infections and pneumonia. This filing highlights the potential of Zaynich as a life-saving antibiotic amid rising antimicrobial resistance concerns.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Wockhardt Limited has informed the Exchange regarding a press release dated January 13, 2025, titled Zaynich? (Zidebactam/Cefepime, WCK 5222) achieves over 97% Efficacy in Clinical Study for serious infections caused by Meropenem-Resistant Gram-Negative Pathogens .".

Wockhardt Limited on 6ix

Earlier from Wockhardt

Later from Wockhardt

All Wockhardt news releases